Boston Scientific announces conference call discussing second quarter 2025 results
Boston Scientific (NYSE:BSX) has scheduled a conference call to discuss its second quarter 2025 financial results and business highlights. The call will take place on July 23, 2025, at 8:00 a.m. ET, featuring Chairman and CEO Mike Mahoney and CFO Jon Monson.
The company will release its Q2 2025 financial results prior to the conference call. Investors can access both the live webcast and replay through the company's investor relations website, with the replay becoming available approximately one hour after the event concludes.
Boston Scientific (NYSE:BSX) ha programmato una conference call per discutere i risultati finanziari e i principali eventi del secondo trimestre 2025. La chiamata si terr脿 il 23 luglio 2025 alle 8:00 AM ET, con la partecipazione del Presidente e CEO Mike Mahoney e del CFO Jon Monson.
L'azienda pubblicher脿 i risultati finanziari del secondo trimestre 2025 prima della conference call. Gli investitori potranno seguire sia la diretta web che la registrazione tramite il sito web delle relazioni con gli investitori della societ脿; la registrazione sar脿 disponibile circa un'ora dopo la conclusione dell'evento.
Boston Scientific (NYSE:BSX) ha programado una llamada de conferencia para discutir sus resultados financieros y aspectos destacados del segundo trimestre de 2025. La llamada tendr谩 lugar el 23 de julio de 2025 a las 8:00 a.m. ET, con la participaci贸n del presidente y CEO Mike Mahoney y el CFO Jon Monson.
La compa帽铆a publicar谩 sus resultados financieros del segundo trimestre de 2025 antes de la llamada. Los inversores podr谩n acceder tanto a la transmisi贸n en vivo como a la repetici贸n a trav茅s del sitio web de relaciones con inversores de la empresa, con la repetici贸n disponible aproximadamente una hora despu茅s de que finalice el evento.
Boston Scientific (NYSE:BSX)电� 2025雲� 2攵勱赴 鞛 鞁れ爜 氚� 欤检殧 靷梾 雮挫毄鞚� 雲检潣頃橁赴 鞙勴暅 旎嵓霟办姢 旖滌潉 鞓堨爼頄堨姷雼堧嫟. 旖滌潃 2025雲� 7鞗� 23鞚� 鞓れ爠 8鞁� ET鞐� 歆勴枆霅橂┌, 須岇灔 瓴� CEO 毵堨澊韥� 毵ろ樃雼堨檧 CFO 臁� 氇姩鞚� 彀胳劃頃╇媹雼�.
須岇偓电� 旎嵓霟办姢 旖� 鞝勳棎 2025雲� 2攵勱赴 鞛 鞁れ爜鞚� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛惖鐢 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 靸濎瓿� 氚� 雲鬼檾 氚╈啞鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, 雲鬼檾 氚╈啞鞚� 頄夓偓 膦呺 鞎� 1鞁滉皠 頉勳棎 鞝滉车霅╇媹雼�.
Boston Scientific (NYSE:BSX) a programm茅 une conf茅rence t茅l茅phonique pour discuter des r茅sultats financiers et des faits marquants du deuxi猫me trimestre 2025. L'appel aura lieu le 23 juillet 2025 脿 8h00 ET, avec la participation du pr茅sident-directeur g茅n茅ral Mike Mahoney et du directeur financier Jon Monson.
La soci茅t茅 publiera ses r茅sultats financiers du deuxi猫me trimestre 2025 avant la conf茅rence t茅l茅phonique. Les investisseurs pourront acc茅der 脿 la diffusion en direct ainsi qu'脿 la rediffusion via le site web des relations investisseurs de l'entreprise, la rediffusion 茅tant disponible environ une heure apr猫s la fin de l'茅v茅nement.
Boston Scientific (NYSE:BSX) hat eine Telefonkonferenz zur Besprechung der Finanzergebnisse und Gesch盲ftshighlights des zweiten Quartals 2025 angesetzt. Die Konferenz findet am 23. Juli 2025 um 8:00 Uhr ET statt, mit dem Vorsitzenden und CEO Mike Mahoney sowie dem CFO Jon Monson.
Das Unternehmen wird die Finanzergebnisse f眉r das 2. Quartal 2025 vor der Telefonkonferenz ver枚ffentlichen. Investoren k枚nnen sowohl den Live-Webcast als auch die Aufzeichnung 眉ber die Investor-Relations-Website des Unternehmens verfolgen; die Aufzeichnung wird etwa eine Stunde nach Ende der Veranstaltung verf眉gbar sein.
- None.
- None.
A live webcast and replay for the event will be accessible at . The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com听and connect on and . 听
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
[email protected]
Lauren Tengler
Investor Relations
+1 (508) 683-4479
[email protected]听
听
View original content to download multimedia:
SOURCE Boston Scientific Corporation
FAQ
When is Boston Scientific (BSX) reporting Q2 2025 earnings?
Who will host Boston Scientific's Q2 2025 earnings call?
How can investors access Boston Scientific's Q2 2025 earnings call?
When will the replay of BSX's Q2 2025 earnings call be available?
